Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EAU guidelines on prostate cancer.

G Aus1, C C Abbou, D Pacik

  • 1Department of Urology, Ryhov Hospital, Jönköping, Sweden. gunnar.aus@ryhov.ltjkpg.se

European Urology
|August 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [<sup>18</sup>F]SiTATE.

European radiology·2024
Same author

External validation of nomograms including MRI features for the prediction of side-specific extraprostatic extension.

Prostate cancer and prostatic diseases·2023
Same author

[Melanosis of the bladder-a rare diagnosis].

Urologie (Heidelberg, Germany)·2023
Same author

Outcome groups and a practical tool to predict success of shock wave lithotripsy in daily clinical routine.

World journal of urology·2020
Same author

Advanced non-contrasted computed tomography post-processing by CT-Calculometry (CT-CM) outperforms established predictors for the outcome of shock wave lithotripsy.

World journal of urology·2018
Same author

Specific learning curve for port placement and docking of da Vinci(®) Surgical System: one surgeon's experience in robotic-assisted radical prostatectomy.

Journal of robotic surgery·2016
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
Same journal

Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.

European urology·2026
See all related articles

These clinical guidelines offer a comprehensive approach to managing prostate cancer patients. They cover diagnosis, staging, treatment options like active monitoring, and follow-up strategies to support patient care.

Area of Science:

  • Urology
  • Oncology

Background:

  • Prostate cancer is a prevalent malignancy in men, necessitating clear management protocols.
  • Existing literature and international guidelines formed the basis for these recommendations.

Framework:

  • Clinical guidelines developed by a working panel using MEDLINE literature review.
  • Panel consensus was utilized to address evidence gaps or low-quality data.

Implementation:

  • Diagnosis relies on histopathological or cytological examination.
  • Staging (N- and M-) can be omitted in select low-risk patients.
  • Treatment strategies range from active treatment to active monitoring for specific patient groups.
  • Follow-up includes history, prostate-specific antigen levels, and digital rectal examination; routine imaging is not advised for asymptomatic patients.

Related Experiment Videos

Implications:

  • Provides essential support for clinicians managing prostate cancer.
  • Aims to standardize and improve patient care pathways.
  • Highlights the importance of individualized treatment and monitoring strategies.